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share knowledge and experience in translational
study of neurodegenerative diseases
Shengdi Chen1* and Jialin C Zheng2
A common feature of current biomedical science is
inter-disciplinary research and collaboration. Transla-
tional research, the basis for translational medicine, inte-
grates the basic sciences and clinical medicine with the
aim of optimizing preventive measures and patient care,
is at the cusp for expansion. Translational medicine, in
short, is the process of turning appropriate biological
discoveries into drugs and medical devices that can be
used in the treatment of patients. Vigorous efforts have
been made to link basic scientific research with clinical
investigations. Notably, in the area of neurodegenerative
disorders, more basic and clinical researchers as well as
nations have joined forces to explore the interface
between basic neurosciences and clinical neurology and
psychology. Thus, the newly established journal of
Translational Neurodegeneration will provide a perfect
platform at the global level to share knowledge and
experience of the latest research on the epidemiology,
etiology, pathogenesis, diagnosis, management and pre-
vention of neurodegenerative diseases.
Indeed, the prevalence of neurodegenerative disorders,
including Alzheimer’s disease (AD) and Parkinson’s dis-
ease (PD), has increased significantly as global popula-
tions age. Specifically, the number of cases of dementia
in the developed world is projected to rise from 13.5
million in 2000 to 21.2 million in 2025, and to 36.7 mil-
lion in 2050[1]. Currently, the number of deaths caused
by AD is only next to the number of deaths caused by
stroke. As the prevalence of AD grows, so does the cost
to a nation. For PD, the second most common neurode-
generative disease after AD, more than 4 million people
suffer from this devastating disease worldwide and that
will double in the next 25 years [2]. To date, PD is still
an incurable progressive neurological disorder that ser-
iously impairs the quality of life.
The discovery and application of levodopa (L-dopa) is
one of the best examples of translational research for
neurodegenerative diseases. In 1910s, L-dopa was first
isolated from seedlings of Vicia faba; and in 1938, L-
dopa decarboxylase was discovered, which can produce
dopamine (DA) from L-dopa. In 1959, DA was found
enriched in the basal ganglia; and in 1960, a severe stria-
tal DA deficit was demonstrated in PD patients. These
major discoveries and a deepening understanding of the
neurochemistry of DA and the neuropathology of PD
led to the concept of “DA replacement” with L-dopa. In
1961, L-dopa was tried in PD patients by i.v. treatment.
In 1967, oral administration of L-dopa was reported to
produce dramatic improvements in PD patients with
increasing amounts over long periods [3]. However, the
main side effects of increasing L-dopa administration, i.
e., dyskinesias and motor fluctuations, became apparent.
This clinical finding confused doctors and patients, and
a solution was needed. In 1970s, the key cause was
found. L-dopa decarboxylase degraded L-dopa to DA in
peripheral blood, which can not across the blood-brain
barrier. These findings led to the first L-dopa combina-
tion, benserazide/L-dopa or carbidopa/L-dopa by adding
a dopa decarboxylase inhibitor to treatment, which
showed advantages in reducing side effects and gaining
better symptom control [4]. Since then, PD researchers
have attempted to overcome complications with such
techniques as continuous L-dopa infusion and, most
recently, long-acting L-dopa combinations.
Substantial progress has been made in understanding
the pathogenesis of neurodegenerative diseases, but we
are still a long way from applying it to clinical applica-
tion. Translational research will definitely help overcome
the bottleneck and barriers in 1) identifing and validat-
ing biomarkers for early or pre-clinical diagnosis as well
as clinical progression; 2) promoting the innovative
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clinical technologies, such as neuroimaging, stem cell
technology and nanotechnology; and 3) developing the
novel drug candidates; and more importantly, to gain a
multitude of new ideas and contacts back to research.
Thus, launching a journal in translational neurodegen-
erative diseases is essential and timely.
The latest research on the etiology, pathogenesis,
potential diagnostic markers and treatment modalities of
PD has been presented at the XIX World Congress on
Parkinson’s Diseases and Related Disorders. Almost
2500 distinguished scientists, clinicians and allied health
experts gathered in Shanghai, China, December 11-14,
2011 to enhance collaboration in these important inter-
disciplinary research areas. Organized by the Association
of Parkinsonism and Related Disorders and the local
host, the Department of Neurology, Ruijin Hospital
affiliated to Shanghai Jiao Tong University School of
Medicine, the congress is the highest level of academic
conferences in the field of PD and related disorders.
Several speakers and attendees contributed review and
original articles for the inaugural issue of Translational
Neurodegeneration. Notably, the articles are interdisci-
plinary and focus on many current issues facing transla-
tional neuroscience research.
Research of gene mutation, especially of alpha-synu-
clein, has provided important clues in understanding the
pathogenesis of PD. In cell models, A53T mutation of
alpha-synuclein can increase macroautophagy, which
has not yet been detected in patients. Yue Huang et al
[5]aimed in their article “Macroautophagy in sporadic
and the genetic form of Parkinson’s disease with the
A53T a-synuclein mutation” to confirm the above
changes in brain tissue of PD patients. Interestingly,
they couldn’t find any evidence to support the conclu-
sion that alpha-synuclein is removed by macroauto-
phagy; and the results may be opposite to the previous
reports. This is followed by a review, provided by Dr.
Shu-Leong Ho’s group, titled “Mitochondrial neuronal
uncoupling proteins: a target for potential disease-modi-
fication in Parkinson’s disease” [6]. It gave a brief insight
into the role of mitochondrial dysfunction and oxidative
stress in the converging pathogenic processes involved
in PD and demonstrated that mitochondrial uncoupling
proteins (UCPs) may play a vital role in protecting neu-
rons from various pathogenic stresses including those
associated with PD. UCPs would be another potential
target for the treatment of these neurological disorders.
Peter A. LeWitt discussed the wide role of norepi-
nephrine (NE) in his review titled “Norepinephrine: the
next therapeutics frontier for Parkinson’s disease” [7].
NE may affect both the motor and non-motor functions,
such as cognition, depression, circadian rhythms, and
orthostatic hypotension. More importantly, drugs like b-
adrenoceptor antagonist and a2-adrenergic receptor
antagonists might help to ameliorate motor, cognitive,
and affective features of PD, suggesting NE’s potential
role in the treatment of motor and non-motor symp-
toms of PD.
Jon Stoessl introduced the latest progress in “Neuroi-
maging in the early diagnosis of neurodegenerative dis-
eases” [8]. SPECT and PET technologies have been
widely used to assess the pre-and post-synaptic abnorm-
alities of transmission to differentiate PD from the Par-
kinson-plus syndromes. DTI (diffusion tensor imaging),
fMRI, task-free fMRI and FDG-PET may also provide
help in the differential diagnosis of degenerative demen-
tias. The use of multimodal imaging, especially when
combined with other biomarkers, showed increasing
promise for the early diagnosis of neurodegenerative
diseases.
Translational research and knowledge of neurodegen-
eration are expanding at a fast pace. The potential to
find causes, treatments and cures for many neurological
and neurodegenerative diseases are available to us. This
congress and our journal highlight the opportunities for
interdisciplinary and global collaborations. By offering a
high-visibility forum for new insights and discussions of
translational research in neurodegenerative diseases,
Translational Neurodegeneration will promote the rapid
conversion of basic research to clinical applications ben-
efiting patients better and faster. The concept and spirit
of translational research in the field of neurodegenera-
tive disorders will spread through Translational Neuro-
degeneration and the authors.
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